RaySearch Laboratories ABRSLBF +0.81%92 PB Ratio is 6.49 as of Jul. 03, 2026, which is 9% above its 10-year median of 5.94. GuruFocus rates RSLBF with a GF Score™ of 92/100 and a GF Value™ of $20.80 (Fairly Valued). The stock has 2 warning signs investors should review. Among 609 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks worse than 88.51% on this metric.
The historical rank and industry rank for RaySearch Laboratories AB's PB Ratio or its related term are showing as below:
RSLBF'
s PB Ratio Range Over the Past 10 Years
Min: 2.22 Med: 5.94 Max: 18.98
Current: 7.23
During the past 13 years, RaySearch Laboratories AB's highest PB Ratio was 18.98. The lowest was 2.22. And the median was 5.94.
RSLBF's PB Ratio is ranked worse than 88.51% of 609
companies
in the Healthcare Providers & Services industry
Industry Median: 1.99
vs RSLBF: 7.23
During the past 12 months, RaySearch Laboratories AB's average Book Value Per Share Growth Rate was 13.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 14.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 8.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 8.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of RaySearch Laboratories AB was 136.30% per year. The lowest was -30.90% per year. And the median was 12.25% per year.
Back to Basics: PB Ratio
RaySearch Laboratories AB (OTCPK:RSLBF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
RaySearch Laboratories AB PB Ratio Related Terms
RaySearch Laboratories AB PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, RaySearch Laboratories AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
RaySearch Laboratories AB (RSLBF) has a PB Ratio of 6.49 as of Jul. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on RaySearch Laboratories AB and its competitors. This is near median its historical median of 5.94. Over the past decade, RaySearch Laboratories AB's PB Ratio has ranged from 2.22 to 18.98. According to the industry distribution chart, RaySearch Laboratories AB ranks #539 out of 609 companies in the Healthcare Providers & Services industry, placing it in the top 88.5%.
Is RaySearch Laboratories AB's PB Ratio too high?
RaySearch Laboratories AB's current PB Ratio of 6.49 is near median its 10-year median of 5.94. Over the past 10 years, this metric has ranged from a low of 2.22 to a high of 18.98. The Healthcare Providers & Services industry median PB Ratio is 1.99. RaySearch Laboratories AB's value of 6.49 is 226.1% above this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #539 out of 609 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, RaySearch Laboratories AB has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's PB Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #539 out of 609 companies for PB Ratio. This places RaySearch Laboratories AB in the lower half of its industry. The industry median PB Ratio is 1.99. RaySearch Laboratories AB's value of 6.49 is 226.1% above this benchmark. Historically, RaySearch Laboratories AB's own PB Ratio has ranged from 2.22 to 18.98 over the past decade. While the company's 10-year median is 5.94 vs. the industry median of 1.99, RaySearch Laboratories AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 1.99, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current PB Ratio of 6.49 is 226.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current PB Ratio is 6.49, which is near median its own 10-year median of 5.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (RSLBF) is currently considered Fairly Valued. The stock's GF Value™ is $20.80, compared to a current price of $21.17 — trading 1.8% above its estimated fair value. The current PB Ratio is 6.49, which is near median its 10-year median of 5.94 and 226.1% above the Healthcare Providers & Services industry median of 1.99. RaySearch Laboratories AB's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For RaySearch Laboratories AB (RSLBF), the current PB Ratio is 6.49 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (RSLBF) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of $21.17 is trading 1.8% above its estimated GF Value™ of $20.80.
GuruFocus considers RaySearch Laboratories AB to be Fairly Valued.
Key valuation signals for RSLBF:
PB Ratio: 6.49 (near median its 10-year median of 5.94)
GF Value™: $20.80 vs. price of $21.17 (1.8% above fair value)
Industry Position: 226.1% above the Healthcare Providers & Services median (#539 of 609)
No single metric tells the full story. See the RSLBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
92GF Score
Get the complete analysis for RSLBF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RSLBF has been successfully added to your 
